156 related articles for article (PubMed ID: 12846993)
1. COX-2 and neurodegeneration in Parkinson's disease.
Teismann P; Vila M; Choi DK; Tieu K; Wu DC; Jackson-Lewis V; Przedborski S
Ann N Y Acad Sci; 2003 Jun; 991():272-7. PubMed ID: 12846993
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Teismann P; Ferger B
Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.
Teismann P; Tieu K; Choi DK; Wu DC; Naini A; Hunot S; Vila M; Jackson-Lewis V; Przedborski S
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5473-8. PubMed ID: 12702778
[TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra.
Feng ZH; Wang TG; Li DD; Fung P; Wilson BC; Liu B; Ali SF; Langenbach R; Hong JS
Neurosci Lett; 2002 Sep; 329(3):354-8. PubMed ID: 12183047
[TBL] [Abstract][Full Text] [Related]
6. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
7. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice.
Feng Z; Li D; Fung PC; Pei Z; Ramsden DB; Ho SL
Neuroreport; 2003 Oct; 14(15):1927-9. PubMed ID: 14561922
[TBL] [Abstract][Full Text] [Related]
8. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
Kubo K; Inada T; Shingu K
Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
[TBL] [Abstract][Full Text] [Related]
9. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.
Przybyłkowski A; Kurkowska-Jastrzebska I; Joniec I; Ciesielska A; Członkowska A; Członkowski A
Brain Res; 2004 Sep; 1019(1-2):144-51. PubMed ID: 15306248
[TBL] [Abstract][Full Text] [Related]
11. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
12. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
[TBL] [Abstract][Full Text] [Related]
13. Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Togashi K; Hasegawa M; Nagai J; Tonouchi A; Masukawa D; Hensley K; Goshima Y; Ohshima T
Genes Cells; 2019 Jan; 24(1):31-40. PubMed ID: 30375127
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.
Hilario WF; Herlinger AL; Areal LB; de Moraes LS; Ferreira TA; Andrade TE; Martins-Silva C; Pires RG
J Mol Neurosci; 2016 Dec; 60(4):453-464. PubMed ID: 27660217
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.
Knott C; Stern G; Wilkin GP
Mol Cell Neurosci; 2000 Dec; 16(6):724-39. PubMed ID: 11124893
[TBL] [Abstract][Full Text] [Related]
18. c-Jun/Bim Upregulation in Dopaminergic Neurons Promotes Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease.
Hu K; Huang Q; Liu C; Li Y; Liu Y; Wang H; Li M; Ma S
Neuroscience; 2019 Feb; 399():117-124. PubMed ID: 30590105
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical findings in the MPTP model of Parkinson's disease.
Schmidt N; Ferger B
J Neural Transm (Vienna); 2001; 108(11):1263-82. PubMed ID: 11768626
[TBL] [Abstract][Full Text] [Related]
20. Neuroinflammatory processes in Parkinson's disease.
Hunot S; Hirsch EC
Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
